Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD5/CD7 CAR-T (EB-BH2026) in Relapsed/Refractory T-ALL and LBL
NCT06420076Phase 2Recruiting
- Sponsor
- Essen BioTech
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of EB-BH2026 in t-cell acute lymphoblastic leukemia (T-ALL), lymphoblastic lymphoma (LL), Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL), sponsored by Essen BioTech. Started Jul 2024; status: recruiting.
02
Drugs
EB-BH2026
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)lymphoblastic lymphoma (LL)Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL)
Beyond the preview
Go deeper on NCT06420076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06420076.